Pacer Advisors Inc. decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 33.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,780 shares of the medical instruments supplier’s stock after selling 2,862 shares during the quarter. Pacer Advisors Inc.’s holdings in West Pharmaceutical Services were worth $1,893,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Northwest Investment Counselors LLC bought a new stake in West Pharmaceutical Services during the third quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new stake in West Pharmaceutical Services during the fourth quarter worth about $34,000. Brooklyn Investment Group bought a new stake in West Pharmaceutical Services during the third quarter worth about $41,000. MassMutual Private Wealth & Trust FSB raised its holdings in West Pharmaceutical Services by 60.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 209 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 79 shares in the last quarter. Finally, Hilltop National Bank raised its holdings in West Pharmaceutical Services by 47.9% during the fourth quarter. Hilltop National Bank now owns 216 shares of the medical instruments supplier’s stock worth $71,000 after acquiring an additional 70 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock opened at $341.88 on Friday. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The stock’s 50 day moving average is $331.42 and its 200-day moving average is $314.12. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $24.76 billion, a price-to-earnings ratio of 50.72, a PEG ratio of 19.71 and a beta of 1.00.
West Pharmaceutical Services Dividend Announcement
Wall Street Analysts Forecast Growth
WST has been the topic of several analyst reports. Bank of America upped their target price on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, December 13th. StockNews.com upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Friday. Wolfe Research initiated coverage on West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Citigroup initiated coverage on West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target on the stock. Finally, UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $430.20.
Check Out Our Latest Report on WST
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
- Five stocks we like better than West Pharmaceutical Services
- What is the FTSE 100 index?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Transportation Stocks Investing
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Best Stocks Under $10.00
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.